We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
Read MoreHide Full Article
Key Takeaways
Soleno Therapeutics stock jumped 56.4% after Neurocrine agreed to acquire it for $53 per share in cash.
NBIX's deal values Soleno at $2.9B and offers a ~34% premium to its April 2 closing price.
Soleno's Vykat XR, a PWS therapy, saw strong uptake with $190M revenues in 2025.
Shares of Soleno Therapeutics (SLNO - Free Report) have surged 56.4% over the past week, driven primarily by the announcement that Neurocrine Biosciences (NBIX - Free Report) has entered into a definitive agreement with Soleno to acquire the company. Per the agreement, NBIX will purchase Soleno for $53.00 per share in cash, valuing the transaction at approximately $2.9 billion. The transaction is expected to be closed in about 90 days, subject to customary conditions and regulatory approvals.
Per the agreement, NBIX will initiate a cash tender offer through a subsidiary to acquire all outstanding shares of Soleno Therapeutics. The offer price represents a premium of approximately 34% to Soleno’s closing price on April 2, 2026, and about 51% to its 30-day volume-weighted average price, highlighting the attractive valuation offered to shareholders. The premium boosted investors’ sentiment.
Year to date, shares of SLNO have risen 13.1% compared with the industry’s 0.2% growth.
Image Source: Zacks Investment Research
NBIX Boosts Rare Disease Portfolio With SLNO’s Vykat XR
The acquisition is expected to further strengthen Neurocrine Biosciences’ leadership in endocrinology and rare diseases while advancing a more diversified portfolio of first-in-class therapies. Under the agreement, NBIX will add Soleno’s Vykat XR (diazoxide choline),a first-in-class treatment for hyperphagia associated with Prader-Willi syndrome (PWS), to its commercial portfolio. It is the first and only FDA-approved therapy for hyperphagia in patients with PWS in the United States.
Following the FDA approval and successful U.S. launch in the second quarter of 2025, Vykat XR has shown strong early adoption, generating $190 million in revenues in 2025.
Per Soleno management, Neurocrine Biosciences is well-positioned to expand the reach of Vykat XR in the PWS community, given its strong expertise in endocrinology and rare diseases and proven commercial execution. Leveraging Neurocrine’s established medical and commercial infrastructure, the therapy is expected to further improve outcomes for patients with PWS while delivering sustained long-term value to shareholders after the transaction closes.
Backed by a robust intellectual property portfolio extending into the mid-2040s, it offers a sustainable platform for long-term value creation.
PWS is a rare genetic neurodevelopmental disorder marked by uncontrollable hunger (hyperphagia), along with cognitive, behavioral and metabolic impairments.
Neurocrine is expected to build a strong commercial portfolio anchored by three key marketed products—Ingrezza, Crenessity and Vykat XR.
NBIX’s Ingrezza is a leading VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease, while Crenessity is approved for congenital adrenal hyperplasia, with both therapies contributing significantly to 2025 revenues.
The addition of Vykat XR further aligns with Neurocrine’s expertise at the intersection of neuroscience and endocrinology. Along with Crenessity and its expanding endocrinology pipeline, Vykat XR is expected to serve as a strong foundation for further strengthening the company’s leadership over time.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 7% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have lost 15.1% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why
Key Takeaways
Shares of Soleno Therapeutics (SLNO - Free Report) have surged 56.4% over the past week, driven primarily by the announcement that Neurocrine Biosciences (NBIX - Free Report) has entered into a definitive agreement with Soleno to acquire the company. Per the agreement, NBIX will purchase Soleno for $53.00 per share in cash, valuing the transaction at approximately $2.9 billion. The transaction is expected to be closed in about 90 days, subject to customary conditions and regulatory approvals.
Per the agreement, NBIX will initiate a cash tender offer through a subsidiary to acquire all outstanding shares of Soleno Therapeutics. The offer price represents a premium of approximately 34% to Soleno’s closing price on April 2, 2026, and about 51% to its 30-day volume-weighted average price, highlighting the attractive valuation offered to shareholders. The premium boosted investors’ sentiment.
Year to date, shares of SLNO have risen 13.1% compared with the industry’s 0.2% growth.
Image Source: Zacks Investment Research
NBIX Boosts Rare Disease Portfolio With SLNO’s Vykat XR
The acquisition is expected to further strengthen Neurocrine Biosciences’ leadership in endocrinology and rare diseases while advancing a more diversified portfolio of first-in-class therapies. Under the agreement, NBIX will add Soleno’s Vykat XR (diazoxide choline),a first-in-class treatment for hyperphagia associated with Prader-Willi syndrome (PWS), to its commercial portfolio. It is the first and only FDA-approved therapy for hyperphagia in patients with PWS in the United States.
Following the FDA approval and successful U.S. launch in the second quarter of 2025, Vykat XR has shown strong early adoption, generating $190 million in revenues in 2025.
Per Soleno management, Neurocrine Biosciences is well-positioned to expand the reach of Vykat XR in the PWS community, given its strong expertise in endocrinology and rare diseases and proven commercial execution. Leveraging Neurocrine’s established medical and commercial infrastructure, the therapy is expected to further improve outcomes for patients with PWS while delivering sustained long-term value to shareholders after the transaction closes.
Backed by a robust intellectual property portfolio extending into the mid-2040s, it offers a sustainable platform for long-term value creation.
PWS is a rare genetic neurodevelopmental disorder marked by uncontrollable hunger (hyperphagia), along with cognitive, behavioral and metabolic impairments.
Neurocrine is expected to build a strong commercial portfolio anchored by three key marketed products—Ingrezza, Crenessity and Vykat XR.
NBIX’s Ingrezza is a leading VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease, while Crenessity is approved for congenital adrenal hyperplasia, with both therapies contributing significantly to 2025 revenues.
The addition of Vykat XR further aligns with Neurocrine’s expertise at the intersection of neuroscience and endocrinology. Along with Crenessity and its expanding endocrinology pipeline, Vykat XR is expected to serve as a strong foundation for further strengthening the company’s leadership over time.
Soleno Therapeutics, Inc. Price and Consensus
Soleno Therapeutics, Inc. price-consensus-chart | Soleno Therapeutics, Inc. Quote
SLNO’s Zacks Rank & Stocks to Consider
Soleno Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) and Indivior Pharmaceuticals (INDV - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 earnings per share have risen from $2.55 to $2.87. CPRX shares have gained 7% year to date.
Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have risen from $2.89 to $3.08. INDV shares have lost 15.1% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 74.53%.